Farallon amendments report ~6.6% TYRA stakes
Tyra Biosciences, Inc. ownership disclosure: an Amendment No. 1 to a Schedule 13G/A filed by Farallon-related entities updates shared beneficial ownership figures for Common Stock (CUSIP 90240B106).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Tyra Biosciences, Inc. ownership disclosure: an Amendment No. 1 to a Schedule 13G/A filed by Farallon-related entities updates shared beneficial ownership figures for Common Stock (CUSIP 90240B106). The filing lists multiple Farallon funds and affiliated persons holding between 74,008 and 3,580,818 shares per line, with several entries showing single-filer holdings of 3,580,818 (representing 6.6%) and 3,407,712 (representing 6.3%).
The filing states the Farallon Funds hold the reported Shares directly and describes the fund/GP/individual relationships and disclaimers of beneficial ownership by certain entities and individuals. The Schedule is filed pursuant to Section 240.13d-1(c) and identifies the Reporting Persons and their principal business office.
Insights
Farallon affiliates report multi‑percent holdings across pooled funds and related managers.
The Amendment updates shared beneficial ownership across several Farallon funds and affiliated GPs, showing individual fund lines such as Farallon Partners, L.L.C. with 3,407,712 shares (6.3%) and multiple individual reporting persons tied to 3,580,818 shares (6.6%). The filing clarifies direct fund holdings and the GP/manager relationships that may give rise to deemed beneficial ownership.
The economic effect depends on whether these pooled funds trade; the filing disclaims affirmative group status and includes standard manager disclaimers. Subsequent filings or transactions would disclose changes to these positions.
Key Figures
Key Terms
Schedule 13G/A regulatory
beneficial owner regulatory
Section 240.13d-1(c) regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Farallon report in TYRA?
Who filed the Schedule 13G/A amendment for TYRA?
Does the filing create a control group among reporting persons?
What address is listed for the Reporting Persons?
AI-generated analysis. How Rhea-AI works. Not financial advice.